CLDX · Celldex Therapeutics
AI read · Bad for CLDX
The AI's read
This weakens the case for developing barzolvolimab for atopic dermatitis because it missed the study's main measures and Celldex's own bar for continuing. The drug remains in study for 3 other conditions, and Celldex has reported positive Phase 3 results there. Those results support other uses, but they do not change the failed result in this one.